Biotech valuations, characterized by their high volatility and dependency on uncertain outcomes, present unique challenges to traditional financial modeling. The inherent risks in drug development, including clinical trial failures, regulatory setbacks, and market dynamics, are compounded by the fact that many outcomes follow distributions with fat tails. Fat-tailed models,

Project management—the noble art of being handed a budget, a timeline, and a goal, then tasked with delivering results while herding cats, pleasing stakeholders, and absorbing the blame when things inevitably go sideways. It’s the quintessential middle-management domain, and if it sounds like I know exactly what

Fat Tails, Black Swans, and Extreme Value Theory (EVT) offer a robust analytical framework for understanding rare, high-impact events that could significantly influence the trajectory of a pharma or biotech company. These concepts focus on the extremes in probability distributions, helping companies and investors better prepare for both catastrophic

When I first considered WhatsApp as a professional communication channel, I was deeply skeptical. It felt too informal, too personal. Could a platform known for family group chats and memes really work for fostering a serious, engaged community? But sometimes, skepticism gives way to opportunity—and in this case, I’

Probability of Launch (POL) is a comprehensive metric designed to estimate the likelihood that a drug successfully completes all clinical trial phases, gains regulatory approval, and enters the market. Unlike Probability of Success (POS), POL extends its scope to incorporate factors beyond regulatory milestones, such as manufacturing readiness, market dynamics,

1. Introduction: The Biotech Valuation Maze Biotech valuation is fraught with complexities that standard financial tools like Discounted Cash Flow (DCF) struggle to address. DCF's reliance on stable revenue curves and Gaussian risk assumptions fails to capture the volatile reality of drug development, where clinical failures, pricing pressures,

Probability of Regulatory Success (PRS) is a metric used to estimate the likelihood that a drug candidate will successfully navigate the regulatory review process and achieve market approval. PRS focuses exclusively on the final stages of the drug development pipeline, where regulatory agencies assess the efficacy, safety, and quality of

Every so often, I wonder if I’m shouting into the void. Not in the performative, social media outrage kind of way, but in the actual sense of watching bad ideas flourish, seeing obvious failures repeat themselves, and knowing that most people will keep playing along—because it’s easier.

When a venture capital (VC) firm or a legal team evaluates an early-stage biotech or pharma startup, due diligence is critical. The stakes are high: investments hinge on scientific credibility, commercial viability, and the ability to navigate regulatory hurdles. This guide details a forensic, red-team approach to uncovering

LinkedIn. The once-practical platform for professional networking has evolved into a peculiar blend of motivational seminar, humblebrag arena, and corporate confessional. You’ve seen the posts: “Starting my next adventure, which taught me so much about resilience and growth.” Or the classic ski-trip reflection: “Connecting with nature in